ArticleThe Lancet regional health. Europe2022
Development of a score for early identification of children with Kawasaki disease requiring second-line treatment in multi-ethnic populations in Europe: A multicentre retrospective cohort study.
Article in The Lancet regional health. Europe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Global epidemiology of myocarditis: disparities in age, sex and geography.Nature reviews. Cardiology · 2026Review
- Clinical factors associated with retreatment and early coronary outcomes in Kawasaki disease in children aged < 6 months: a single-center cohort study.European journal of pediatrics · 2026Article
- Diagnostic approaches to Kawasaki disease worldwide: the results from the JIR-CliPS network.Rheumatology (Oxford, England) · 2026Article
- Comprehensive Assessment of the Risk of Developing Coronary Artery Aneurysm in Kawasaki Disease: A KawaCOR Score Study.Life (Basel, Switzerland) · 2026Article
- An interpretable machine learning model for early risk stratification of medium-to-giant coronary artery aneurysm in Kawasaki disease: development and external validation.Pediatric research · 2026Article
- Performance of Kawasaki Disease Risk Scores in a 30-Year Regional Spanish Cohort.Pediatric cardiology · 2026Article
- Predictive value for intravenous immunoglobulin resistance of Kobayashi and Kawanet scores in 722 children with Kawasaki disease across diverse ethnic backgrounds (KIWI study): an international cohort study.EClinicalMedicine · 2026Article
- Epidemiology of Kawasaki disease in the population of the Caribbean Island of Martinique, 2013-2019.BMC pediatrics · 2026Article
- A nomogram for predicting the risk of persistent coronary artery aneurysms in children with Kawasaki disease: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- An Update on Kawasaki Disease.Current rheumatology reports · 2024Review
- Coronary Arteries Lesions in Kawasaki Disease: Risk Factors in an Italian Cohort.Biomedicines · 2024Article
- Risk factors and scores for prediction of coronary artery aneurysms in Kawasaki disease: a European monocentric study.BMC pediatrics · 2024Article
- Importance of predicting non-response to intravenous immunoglobulin therapy in non-Asian patients with Kawasaki disease.The Lancet regional health. Europe · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification of high-risk patients is essential to stratify treatment algorithms of Kawasaki disease (KD) and to appropriately select patients at risk for complicated disease who would benefit from intensified first-line treatment. Several scores have been developed and validated in Asian populations but have shown low sensitivity in predicting intravenous immunoglobulin (IVIG) resistance in non-Asian populations. We sought methods to predict the need for secondary treatment after initial IVIG in non-Asian populations. Methods: We conducted a retrospective, multicenter study including consecutive patients with KD admitted to two tertiary pediatric hospitals in France and Italy from 2005 to 2019. We evaluated the performance of the Kawanet-score and compared it with the performances of initial echocardiography findings, and of a newly proposed score combining the Kawanet-score and initial echocardiography findings. For each score, we assessed the AUC, sensitivity and specificity for predicting the need for second-line treatment. Findings: We included 363 children with KD, 186 from France and 177 from Italy, of whom 57 (16%) required second-line therapy after the first IVIG dose. The Kawanet score, coronary artery dilation or aneurysm with maximal Z-score ≥2.0 at baseline, and abnormal initial echocardiography had a sensitivity of 43%, 55% and 65% and a specificity of 73%, 78%, 73%, respectively, for predicting the need for second-line treatment. The Kawanet-score was significantly improved by combining it with initial echocardiography findings. The best predictive performance (Sensitivity 76%, Specificity 54%) was obtained by combining the Kawanet-score with abnormal initial echocardiography, defined by the presence of either coronary artery maximal Z-score ≥2.0, pericarditis, myocarditis and/or ventricular dysfunction. This score predicted the need for second-line treatment in European, African/Afro-Caribbean and Asian ethnicity with a sensitivity of 80%, 65% and 100%, respectively, and a specificity of 56%, 51% and 61%, respectively. Interpretation: Our study proposes a score that we named the Kawanet-echo score, which allows early identification of children with KD who require a second-line treatment in multi-ethnic populations in Europe. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.